Immix Therapies Enhance Apoptotic Activity of FDA-Approved Agents by 5X and Catalyze Total Shift in Tumor Micro-Environment
Immix Biopharma, Inc., a Los Angeles-based clinical-stage biopharmeceutical company developing therapies for high unmet medical needs, has recently appointed two world-reknowned oncologists to its Medical Advisory Board. Dr. George Sledge is Professor and Chief of the Division of Oncology at Stanford University Medical Center. Dr. Razelle Kurzrock is Professor and Chief of the Division of Hematology & Oncology at UCSD Moores Cancer Center. Both Drs. Sledge and Kurzrock will provide Immix Biopharma with strategic guidance and insights on critical unmet areas of need in oncology care today.
Immix Biopharma CEO and Co-Founder Dr. Ilya Rachman said, “We are incredibly humbled and enthused to work with such oncology luminaries as Dr. Kurzrock and Dr. Sledge to help fill high unmet needs in the oncology setting. Our approach has been patient-centered from the start, and we are excited to have renowned leaders that share that mission working with us.”
Immix Biopharma is currently enrolling in a phase 1b/2a clinical trial in relapsed-refractory, advanced solid tumors. Immix is also actively pursuing partnerships with other oncology therapeutics firms to help improve the duration and efficacy of their products. In preclinical studies, Immix therapies have demonstrated an ability to enhance apoptotic activity of an already FDA-approved agent by 5x compared to the approved agent alone, in addition to catalyzing a wholesale shift in the tumor micro-environment.
In upcoming news, Immix Biopharma is presenting at the NYC Oncology Investor Conference, occurring on May 8-9 at the office of Wilson Sonsini in New York City. Learn more and register to attend the conference at www.nyconcologyconference.com.